Projects
Using chemogenetics to re-adjust the output of the basal forebrain after cholinergic neuron depletion; University of Antwerp
Identifying prognostic variables for persistent upper limb dysfunctions after breast cancer treatment: body functions, personal and environmental factors according to the International Classification of Functioning, Disease and Health (ICF) KU Leuven
Business development of a drug screening Spin-off company based on 2D & 3D human iPSC-derived liver cell models for NASH & (i)DILI. KU Leuven
Implantable Dural Venous Sinus Access Device (DVSAD), a preclinical assessment of human prototypes. Ghent University
Our objective is to bring the DVSAD to the point that it can be licensed to a third party for commercialisation. The 3 main phases in this trajectory would be prototyping/Intellectual Property (IP), preclinical and clinical testing. The prototyping and IP phases have been covered in the initial StarTT-project. Evaluation and refinement of the prototypes have been the subject of the Advanced-project. This first evaluation led to several new ...
Acute effects of low vs. high nicotine concentrations in liquids in e-cigarettes on self-titration, craving, and satisfaction KU Leuven
Novel platforms for studying AAV subcellular biology & the design of improved gene therapy vectors KU Leuven
Adeno-associated virus (AAV) gene therapy is currently experiencing a renaissance thanks to a number of successful clinical trials. However, vector doses required to achieve therapeutic effect are high and some tissues remain difficult targets for efficient transduction. In general, gene therapy strategies directed at the brain of patients with inherited neurological or neurodegenerative disorders have shown limited efficacy. One of the main ...
Ferroptosis: a novel paradigm in the neurodegenerative pathology of Wolfram syndrome KU Leuven
Hybrid CAR – improving cellular therapies for infectious diseases Ghent University
In this project we aim to develop a Chimeric Antigen Receptor (CAR) T cell-based therapy against a viral infection, where virus becomes effectively eliminated from the patient’s organism. CAR T cell therapy has been successfully applied to treatment of haematological malignancies, but its usage to treat viral infections so far has failed clinical trials. The novelty of our approach consists in targeting not only infected host’s cells ...